BioTuesdays

Tag - Ryan Zimmerman

RxSight

Analysts start RxSight at buy

Analysts for BTIG and SVB Leerink launched coverage of RxSight (NASDAQ:RXST) with “buy” ratings and price targets of $28 and $20, respectively. The stock closed at $11.94 on Aug. 23. RxSight has developed the Light...

Vericel Logo

BTIG ups Vericel PT to $30 from $23

BTIG raised its price target for Vericel (NASDAQ:VCEL) to $30 from $23 after an analyst and investor event focused primarily on NexoBrid, a recently licensed burn enzymatic debridement product from MediWound. ...

Avita Medical

BTIG starts Avita Medical at buy; PT $10

BTIG launched coverage of Avita Medical (NASDAQ:RCEL) with a “buy” rating and $10 price target. The stock closed at $8.32 on March 2. Avita’s RECELL system produces a suspension of spray-on-skin cells using a small...

STAAR Surgical

BTIG starts STAAR Surgical at buy: PT $46

BTIG initiated coverage of STAAR Surgical (NASDAQ:STAA) with a “buy” rating and $46 price target. The stock closed at $36.82 on Dec. 3. “We believe STAAR owns a superior refractive surgery option to the current standard...

Vericel Logo

BTIG ups Vericel PT to $13 from $8

BTIG raised its price target for Vericel (NASDAQ:VCEL) to $13 from $8 after the company beat consensus estimates for the fourth quarter and provided strong guidance for 2018. The stock was quoted at $11.15, up $2.80, in...